Aurora Spine Corporation (ASAPF)
| Market Cap | 13.81M -20.0% |
| Revenue (ttm) | 18.37M +4.6% |
| Net Income | -731.12K |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Average Volume | 45,045 |
| Open | 0.1801 |
| Previous Close | 0.1775 |
| Day's Range | 0.1801 - 0.1801 |
| 52-Week Range | 0.1659 - 0.2563 |
| Beta | -0.55 |
| RSI | 42.76 |
| Earnings Date | Apr 29, 2026 |
About Aurora Spine
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic pro... [Read more]
Financial Performance
In 2025, Aurora Spine's revenue was $18.37 million, an increase of 4.58% compared to the previous year's $17.56 million. Losses were -$731,120, -27.08% less than in 2024.
Financial StatementsNews
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices ...
Aurora Spine Earnings Call Transcript: Q4 2025
Record annual and Q4 revenues driven by ZIP, SiLO, and DEXA-L launches, with gross margin improvement and narrowed net loss. Expanded sales force and new product launches position the company for continued growth and cash flow positivity in 2026.
Aurora Spine Registration statement: Q4 2025
Aurora Spine filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Aurora Spine Registration statement: Q4 2025
Aurora Spine filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Aurora Spine Earnings release: Q4 2025
Aurora Spine released its Q4 2025 earnings on April 30, 2026, summarizing the period's financial results.
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30th at 11am ET/8am PT –
Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2025 Financial Results
CARLSBAD, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical device...
Aurora Spine Corporation to Participate in the 38th Annual ROTH Conference
CARLSBAD, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical device...
AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Aurora Spine Slides: Investor presentation
Aurora Spine has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.
Aurora Spine Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Significant product launches and portfolio expansion are set for 2026, including new cervical and lumbar implants, biologics, and SI joint solutions. Operational improvements, a growing sales team, and strong clinical research underpin a goal of surpassing $20 million in revenue.
Aurora Spine Announces Issuance of Two U.S. Patents
CARLSBAD, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive spine and interventional pain solu...
Aurora Spine Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 7.1% year-over-year to $4.43M due to a product transition, but gross margin improved to 60.9%. Proprietary launches like Hydra ARO and Dexa L drove record October sales, and the company expects continued growth as adoption expands.
Aurora Spine Earnings release: Q3 2025
Aurora Spine released its Q3 2025 earnings on November 18, 2025, summarizing the period's financial results.
Aurora Spine Registration statement: Q3 2025
Aurora Spine filed a registration statement on November 18, 2025, providing details about a securities offering with the SEC.
Aurora Spine Registration statement: Q3 2025
Aurora Spine filed a registration statement on November 18, 2025, providing details about a securities offering with the SEC.
Aurora Spine Corporation Announces Record Third Quarter Financial Results
- Company to host conference call Today, November 18th at 11am ET/8am PT – - Company to host conference call Today, November 18th at 11am ET/8am PT –
Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
Company to Showcase Cutting-Edge Innovations at Booth #1622 CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), ...
Aurora Spine Launches New Biologics Portfolio
New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integrated Source for Spinal Implants and Biologics New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integr...
Aurora Spine Announces Proposed Warrant Extension
CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain manageme...
Aurora Spine Transcript: Lytham Partners Fall 2025 Investor Conference
Minimally invasive spine devices and new product launches have driven strong revenue growth and margin expansion, with clinical evidence supporting adoption. The company is now focused on sales execution, expanding its sales team and market reach, and expects continued growth as new products roll out.
Aurora Spine Announces Launch of its DEXA-L™ Anterior Lumbar Interbody Fusion Device
Please click here to view image CARLSBAD, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine...
Aurora Spine Earnings Call Transcript: Q2 2025
Q2 2025 saw a 10.2% revenue increase to $4.5M, with improved EBITDA and gross margins. Proprietary products like SiLO-TFX and DEXA-C drove growth, while new launches (Hydra Arrow, DEXA-L) are expected to boost results in late 2025. Cash position and collections remain stable.
Aurora Spine Earnings release: Q2 2025
Aurora Spine released its Q2 2025 earnings on September 2, 2025, summarizing the period's financial results.
Aurora Spine Registration statement: Q2 2025
Aurora Spine filed a registration statement on September 2, 2025, providing details about a securities offering with the SEC.